Sarissa Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Sarissa Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,001,000	Closed	-$970K	–	17
2016 Q1	$970K	Hold	1,001,000	–	–	0.21%	15
2015 Q4	$1.21M	Sell	1,001,000 -131,367	-12%	-$422K	0.24%	16
2015 Q3	$8.41M	Hold	1,132,367	–	–	2.08%	12
2015 Q2	$8.1M	Hold	1,132,367	–	–	1.86%	10
2015 Q1	$9.73M	Hold	1,132,367	–	–	2.05%	10
2014 Q4	$11.3M	Hold	1,132,367	–	–	4%	7
2014 Q3	$11.2M	Buy	1,132,367 +129,000	+13%	+$1.91M	4.33%	7
2014 Q2	$17.4M	Buy	1,003,367 +442,767	+79%	+$7.22M	5.9%	6
2014 Q1	$9.95M	Buy	560,600 +101,092	+22%	+$1.96M	3.42%	8
2013 Q4	$8.41M	Buy	+459,508	New	+$8.68M	3.15%	10

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Sarissa Capital Management's RPRX Position: Q2 2016 in Review

Sarissa Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 1,001,000 shares — an estimated $970K sold.

Sarissa Capital Management first reported a position in RPRX in Q4 2013 and held it in 10 quarters. The position peaked at $17.4M in Q2 2014. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

Sarissa Capital Management reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
Sarissa Capital Management sold 1,001,000 Repros Therapeutics Inc. shares in Q2 2016, an estimated $970K.
Sarissa Capital Management first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 10 quarters.
Sarissa Capital Management's Repros Therapeutics Inc. position peaked at $17.4M in Q2 2014.
43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on Sarissa Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.